Recent Quotes

Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. The company reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Earnings

Q2 2021		Est.		Actual		Surprise
EPS		(EXPECTED)2021-08-04
REV		(EXPECTED)2021-08-04

Q1 2021		Est.		Actual		Surprise
EPS		-0.810		-0.260		0.5500
REV		7.800M		27.966M		20.166M

Analyst Ratings

Date	Analyst Firm	Analyst Name	Action	Rating	Action Price	Prior Price	Target

Related Companies

Ticker	Company	Price	Change	Chg %		Mkt Cap
CLLS	Cellectis	15.18	-0.12	-0.78%		653.3M

Cellectis Frequently Asked Questions

How do I buy Cellectis (CLLS) stock?

You can purchase shares of Cellectis (NASDAQ: CLLS) through any online brokerage.

View our list of the best stock brokerages.

Who are Cellectis's (CLLS) competitors?

Other companies in Cellectis’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Orchard Therapeutics (NASDAQ:ORTX), KalVista Pharmaceuticals (NASDAQ:KALV), TCR2 Therapeutics (NASDAQ:TCRR) and AnaptysBio (NASDAQ:ANAB).

What is the target price for Cellectis (CLLS) stock?

The latest price target for Cellectis (NASDAQ: CLLS) was reported by Guggenheim on April 28, 2021. The analyst firm set a price target for 0.00 expecting CLLS to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.

Current Stock Price for Cellectis (CLLS)?

The stock price for Cellectis (NASDAQ: CLLS) is $15.18 last updated Fri Jun 11 2021 20:00:03 GMT+0000 (Coordinated Universal Time).

Does Cellectis (CLLS) pay a dividend?

There are no upcoming dividends for Cellectis.

When is Cellectis (NASDAQ:CLLS) reporting earnings?

Cellectis’s Q2 earnings are confirmed for after-market on August 4, 2021.

Is Cellectis (CLLS) going to split?

There is no upcoming split for Cellectis.

What sector and industry does Cellectis (CLLS) operate in?

Cellectis is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.